147 related articles for article (PubMed ID: 16332967)
1. CD7-restricted activation of Fas-mediated apoptosis: a novel therapeutic approach for acute T-cell leukemia.
Bremer E; ten Cate B; Samplonius DF; de Leij LF; Helfrich W
Blood; 2006 Apr; 107(7):2863-70. PubMed ID: 16332967
[TBL] [Abstract][Full Text] [Related]
2. Target cell-restricted apoptosis induction of acute leukemic T cells by a recombinant tumor necrosis factor-related apoptosis-inducing ligand fusion protein with specificity for human CD7.
Bremer E; Samplonius DF; Peipp M; van Genne L; Kroesen BJ; Fey GH; Gramatzki M; de Leij LF; Helfrich W
Cancer Res; 2005 Apr; 65(8):3380-8. PubMed ID: 15833872
[TBL] [Abstract][Full Text] [Related]
3. Selective elimination of pathogenic synovial fluid T-cells from rheumatoid arthritis and juvenile idiopathic arthritis by targeted activation of Fas-apoptotic signaling.
Bremer E; Abdulahad WH; de Bruyn M; Samplonius DF; Kallenberg CG; Armbrust W; Brouwers E; Wajant H; Helfrich W
Immunol Lett; 2011 Aug; 138(2):161-8. PubMed ID: 21514322
[TBL] [Abstract][Full Text] [Related]
4. A recombinant CD7-specific single-chain immunotoxin is a potent inducer of apoptosis in acute leukemic T cells.
Peipp M; Küpers H; Saul D; Schlierf B; Greil J; Zunino SJ; Gramatzki M; Fey GH
Cancer Res; 2002 May; 62(10):2848-55. PubMed ID: 12019163
[TBL] [Abstract][Full Text] [Related]
5. Requirement of cell-cell contact in the induction of Jurkat T cell apoptosis: the membrane-anchored but not soluble form of FasL can trigger anti-CD3-induced apoptosis in Jurkat T cells.
Oyaizu N; Kayagaki N; Yagita H; Pahwa S; Ikawa Y
Biochem Biophys Res Commun; 1997 Sep; 238(2):670-5. PubMed ID: 9299572
[TBL] [Abstract][Full Text] [Related]
6. [Expression of Fas receptor and soluble Fas ligand (sFasL) concentration in acute leukemia].
Urbaniak-Kujda D; Jaźwiec B; Tomaszewska-Toporska B; Wołowiec D; Kapelko-Słowik K; Kuliczkowski K
Pol Arch Med Wewn; 2002 Sep; 108(3):873-8. PubMed ID: 12600184
[TBL] [Abstract][Full Text] [Related]
7. [The expression and application of human Fas ligand in E.coli].
Li NL; Nie H; Yu QW; Bo J; Ma AL; Zhang JY; Shen BH; Wang L; Zhang DQ
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2003 Jan; 19(1):20-2. PubMed ID: 15132896
[TBL] [Abstract][Full Text] [Related]
8. Soluble Fas/Apo-1 (CD95) levels during T cell activation in the presence of acute myelogenous leukemia accessory cells; contributions from local release and variations in systemic levels.
Bruserud O; Ulvestad E
Cancer Immunol Immunother; 2000 Sep; 49(7):377-87. PubMed ID: 10999464
[TBL] [Abstract][Full Text] [Related]
9. Role of soluble Fas ligand in autoimmune diseases.
Li NL; Nie H; Yu QW; Zhang JY; Ma AL; Shen BH; Wang L; Bai J; Chen XH; Zhou T; Zhang DQ
World J Gastroenterol; 2004 Nov; 10(21):3151-6. PubMed ID: 15457562
[TBL] [Abstract][Full Text] [Related]
10. Novel CD7-specific nanobody-based immunotoxins potently enhanced apoptosis of CD7-positive malignant cells.
Tang J; Li J; Zhu X; Yu Y; Chen D; Yuan L; Gu Z; Zhang X; Qi L; Gong Z; Jiang P; Yu J; Meng H; An G; Zheng H; Yang L
Oncotarget; 2016 Jun; 7(23):34070-83. PubMed ID: 27083001
[TBL] [Abstract][Full Text] [Related]
11. Fas ligand is highly expressed in acute leukemia and during the transformation of chronic myeloid leukemia to blast crisis.
Lickliter JD; Kratzke RA; Nguyen PL; Niehans GA; Miller JS
Exp Hematol; 1999 Oct; 27(10):1519-27. PubMed ID: 10517493
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of Fas/Fas ligand-mediated apoptotic cell death of lymphocytes in vitro by circulating anti-Fas ligand autoantibodies in patients with systemic lupus erythematosus.
Suzuki N; Ichino M; Mihara S; Kaneko S; Sakane T
Arthritis Rheum; 1998 Feb; 41(2):344-53. PubMed ID: 9485093
[TBL] [Abstract][Full Text] [Related]
13. Fas ligand is constitutively secreted by prostate cancer cells in vitro.
Liu QY; Rubin MA; Omene C; Lederman S; Stein CA
Clin Cancer Res; 1998 Jul; 4(7):1803-11. PubMed ID: 9676859
[TBL] [Abstract][Full Text] [Related]
14. Superior activity of fusion protein scFvRit:sFasL over cotreatment with rituximab and Fas agonists.
Bremer E; ten Cate B; Samplonius DF; Mueller N; Wajant H; Stel AJ; Chamuleau M; van de Loosdrecht AA; Stieglmaier J; Fey GH; Helfrich W
Cancer Res; 2008 Jan; 68(2):597-604. PubMed ID: 18199557
[TBL] [Abstract][Full Text] [Related]
15. Fas ligand in human serum.
Tanaka M; Suda T; Haze K; Nakamura N; Sato K; Kimura F; Motoyoshi K; Mizuki M; Tagawa S; Ohga S; Hatake K; Drummond AH; Nagata S
Nat Med; 1996 Mar; 2(3):317-22. PubMed ID: 8612231
[TBL] [Abstract][Full Text] [Related]
16. Mechanism of counterattack of colorectal cancer cell by Fas/Fas ligand system.
Zhu Q; Liu JY; Xu HW; Yang CM; Zhang AZ; Cui Y; Wang HB
World J Gastroenterol; 2005 Oct; 11(39):6125-9. PubMed ID: 16273638
[TBL] [Abstract][Full Text] [Related]
17. Apoptosis of antigen-specific T lymphocytes upon the engagement of CD8 by soluble HLA class I molecules is Fas ligand/Fas mediated: evidence for the involvement of p56lck, calcium calmodulin kinase II, and Calcium-independent protein kinase C signaling pathways and for NF-kappaB and NF-AT nuclear translocation.
Contini P; Ghio M; Merlo A; Poggi A; Indiveri F; Puppo F
J Immunol; 2005 Dec; 175(11):7244-54. PubMed ID: 16301629
[TBL] [Abstract][Full Text] [Related]
18. Considering Fas ligand as a target for therapy.
Linkermann A; Qian J; Lettau M; Kabelitz D; Janssen O
Expert Opin Ther Targets; 2005 Feb; 9(1):119-34. PubMed ID: 15757486
[TBL] [Abstract][Full Text] [Related]
19. Host-mediated antibody-dependent cellular cytotoxicity contributes to the in vivo therapeutic efficacy of an anti-CD7-saporin immunotoxin in a severe combined immunodeficient mouse model of human T-cell acute lymphoblastic leukemia.
Flavell DJ; Warnes S; Noss A; Flavell SU
Cancer Res; 1998 Dec; 58(24):5787-94. PubMed ID: 9865737
[TBL] [Abstract][Full Text] [Related]
20. Soluble Fas-ligand (sFasL) in human astrocytoma cyst fluid is cytotoxic to T-cells: another potential means of immune evasion.
Frankel B; Longo SL; Canute GW
J Neurooncol; 2000 May; 48(1):21-6. PubMed ID: 11026693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
